Hypersensitivity to the active substance(s) or to any of the excipients listed in Description.
Patients with uncontrolled hypertension (see Precautions).
Patients with a current seizure disorder or a history of seizures (see Precautions).
Patients with a known central nervous system tumour.
Patients undergoing acute alcohol or benzodiazepine withdrawal.
Patients with a history of bipolar disorder.
Patients receiving any concomitant treatment containing bupropion or naltrexone.
Patients with a current or previous diagnosis of bulimia or anorexia nervosa.
Patients currently dependent on chronic opioids (see Precautions and Interactions) or opiate agonists (e.g., methadone), or patients in acute opiate withdrawal.
Patients receiving concomitant administration of monoamine oxidase inhibitors (MAOI). At least 14 days should elapse between discontinuation of MAOI and initiation of treatment with naltrexone/bupropion (see Interactions).
Patients with severe hepatic impairment (see Dosage & Administration and Pharmacology: Pharmacokinetics under Actions).
Patients with end-stage renal failure (see Dosage & Administration and Pharmacology: Pharmacokinetics under Actions).